 Curis Inc NASDAQ: CRIS stock gained momentum yesterday in reaction to updated data from its Phase 12 study of CA-4948 in patients with acute myeloid leukemia AML or high-risk myelodysplastic syndromes MDS. Four objective responses were recorded with signs of hematologic recovery. 